These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 18383849

  • 1. PAI-1, t-PA and circulating hTERT DNA as related to virus infection in liver carcinogenesis.
    Divella R, Lacalamita R, Tommasi S, Coviello M, Daniele A, Garrisi VM, Abbate I, Simone G, Gadaleta C, Paradiso A, Quaranta M.
    Anticancer Res; 2008; 28(1A):223-8. PubMed ID: 18383849
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma.
    Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Stark M, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T, Oka M.
    Anticancer Res; 2006; 26(6C):4713-9. PubMed ID: 17214331
    [Abstract] [Full Text] [Related]

  • 5. Circulating transforming growth factor-β and epidermal growth factor receptor as related to virus infection in liver carcinogenesis.
    Divella R, Daniele A, Gadaleta C, Tufaro A, Venneri MT, Paradiso A, Quaranta M.
    Anticancer Res; 2012 Jan; 32(1):141-5. PubMed ID: 22213299
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-I (PAI-I) levels in plasma and peritoneal effluent in patients on CAPD.
    Selgas R, Cuesta MV, Riñon C, Romero JR, de Alvaro F, Bajo MA, Sanchez-Sicilia L.
    Adv Perit Dial; 1992 Jan; 8():160-5. PubMed ID: 1361777
    [Abstract] [Full Text] [Related]

  • 8. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW, Helmy A, Ludlam C, Webb DJ, Hayes PC, Newby DC.
    Thromb Res; 2008 Jan; 121(5):675-80. PubMed ID: 17870147
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Plasminogen activator and plasminogen activator inhibitor gene expression in human saphenous vein organ culture.
    Javed Q, Swanson N, Warner EL, Gershlick AH, de Bono DP.
    Exp Mol Pathol; 2001 Apr; 70(2):146-53. PubMed ID: 11263957
    [Abstract] [Full Text] [Related]

  • 11. Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma.
    Miura N, Maruyama S, Oyama K, Horie Y, Kohno M, Noma E, Sakaguchi S, Nagashima M, Kudo M, Kishimoto Y, Kawasaki H, Hasegawa J, Shiota G.
    Oncology; 2007 Apr; 72 Suppl 1():45-51. PubMed ID: 18087181
    [Abstract] [Full Text] [Related]

  • 12. Abnormal expression of hepatomas and circulating telomerase and its clinical values.
    Wu W, Yao DF, Qiu LW, Wu XH, Yao M, Su XQ, Zou L.
    Hepatobiliary Pancreat Dis Int; 2005 Nov; 4(4):544-9. PubMed ID: 16286259
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
    Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K.
    Scand J Gastroenterol; 2008 Nov; 43(7):849-56. PubMed ID: 18584524
    [Abstract] [Full Text] [Related]

  • 15. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ.
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels.
    Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, Vaughan DE, van Gilst WH, Moore JH.
    Thromb Haemost; 2006 Oct; 96(4):471-7. PubMed ID: 17003924
    [Abstract] [Full Text] [Related]

  • 18. Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies.
    Murugavel KG, Mathews S, Jayanthi V, Shankar EM, Hari R, Surendran R, Vengatesan A, Raghuram K, Rajasambandam P, Murali A, Srinivas U, Palaniswamy KR, Pugazhendhi T, Thyagarajan SP.
    Int J Infect Dis; 2008 Nov; 12(6):e71-6. PubMed ID: 18658001
    [Abstract] [Full Text] [Related]

  • 19. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status.
    Saini N, Srinivasan R, Chawla Y, Sharma S, Chakraborti A, Rajwanshi A.
    Liver Int; 2009 Sep; 29(8):1162-70. PubMed ID: 19627485
    [Abstract] [Full Text] [Related]

  • 20. Serum PAI-1 and PAI-1 4G/5G Polymorphism in Hepatitis C Virus-Induced Cirrhosis and Hepatitis C Virus-Induced Hepatocellular Carcinoma Patients.
    El Edel RH, Essa ES, Essa AS, Hegazy SA, El Rowedy DI.
    Viral Immunol; 2016 Nov; 29(9):510-515. PubMed ID: 27459171
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.